Global Pediatric Oncology Drugs Market is segmented By Drug Type (Eflornithine [Iwilfin], Entrectinib [Rozlytrek], Nivolumab [Opdivo], Bosutinib [Bosulif], Dabrafenib [Tafinlar], Others) By Indication (Leukemia, Lymphoma, Brain Tumors, Neuroblastoma, Wilms Tumor, Others) By Route of Administration (Oral, Topical, Intravenous, Others) By End User (Hospitals, Specialty Clinics, Cancer Research Institutes, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Global Pediatric Oncology Drugs Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031
Paediatric oncology is the branch of medicine dedicated to diagnosing and treating cancer in children. Childhood cancer, though rare compared to adult cancer, presents unique challenges due to the developmental stage of young patients and the distinct nature of paediatric tumours.
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Drug Type, Indication, Route of Administration, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rise of innovations in pediatric oncology
Advancements in medical research, such as genomics, immunotherapy, and targeted therapies, are revolutionizing pediatric oncology, resulting in more effective and less toxic treatments for children with cancer.
Precision oncology is one of the advancements in pediatric oncology where the goal of precision oncology is to identify drugs predicted to work against tumours with specific mutations, etc. As noted above, The MATCH trial has demonstrated the feasibility of identifying personalised therapeutic options for pediatric patients with difficult-to-treat cancer.
Examples of recent precision oncology success stories in pediatric oncology include the utilization of NTRK inhibitors for rare NTRK pediatric solid tumours, such as infantile fibrosarcoma and RAF/MEK inhibitors for the treatment of low-grade gliomas in children.
Lack of professionals
Primary care infrastructure needs improvement, and primary care providers should be educated to recognize pediatric malignancies and provide appropriate referrals. Formal research training for physicians in newly developed pediatric oncology units is also lacking. Fellowship training programs should consider additional clinical and research experiences to expand expertise in designing and conducting research to improve patient outcomes.
Segment Analysis
The global pediatric oncology drugs market is segmented based on drug type, indication, route of administration end-user and region.
The Eflornithine [Iwilfin] from the drug type segment accounted for approximately 32.3% of the pediatric oncology drugs market share
The Eflornithine [Iwilfin] from the drug type segment accounted for approximately 32.3%. Eflornithine is a type of targeted therapy called a kinase inhibitor. A kinase is an enzyme that promotes cell growth. There are many types of kinases, which control different phases of cell growth.
For instance, in December 2023, the Food and Drug Administration approved eflornithine (IWILFIN, USWM, LLC) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like drug launches, FDA approvals, prevalence of pediatric neuroblastoma and the region's advanced medical facilities. This is due to positive government initiatives and an increase in research collaboration. The U.S. holds the highest share in this area because of its patient population, supportive legislation, and advanced healthcare market.
For instance, in March 2024, Caris Life Sciences, a leading AI TechBio company, announced a collaboration with the Beat Childhood Cancer Research Consortium, a network of over 50 universities and children's hospitals based at Penn State College of Medicine, to develop innovative solutions for healthcare and human condition improvement using molecular science and AI.
Moreover, in December 2023, U.S. Food and Drug Administration (FDA) approved the first drug based on Sholler’s research and clinical trials she led through the Beat Childhood Cancer Research Consortium — to reduce the risk of relapse for pediatric high-risk neuroblastoma patients.
Covid 19 Impact Analysis
COVID-19 had a significant effect on the world’s pediatric oncology healthcare workforce, with deleterious effects felt across. COVID-19 and pediatric oncology providers of all country income groups, reflecting the truly global nature of the pandemic’s impact. To prevent potentially devastating impacts, it is imperative that healthcare organizations around the world implement measures that support providers, both as the current pandemic evolves and in planning for future catastrophic events.
Competitive Landscape
The major global players in the market include US WorldMeds, Novartis, Bristol Myers Squibb, Pfizer Inc., ORPHELIA Pharma, Day One Pharmaceuticals, Celon Labs, United Therapeutics, Y-mAbs Therapeutics, Inc., Servier Pharmaceuticals LLC among others.
Key Developments
- In March 2024, Pune-based Gennova Biopharmaceuticals announced the launch of India’s first paediatric pack size of pegaspargase, HAMSYL – Junior, which will now be available in a 1500 IU pack size. This marks a significant milestone in advancing healthcare for Indian children suffering from an orphan disease called Acute Lymphoblastic Leukaemia (ALL), a rare and challenging form of blood cancer primarily affecting children.
- In September 2023, Cincinnati Children’s, the top-ranked pediatric hospital and top-ranked cancer program in the country by U.S. News & World Report, launched its first-of-its-kind Advanced Leukemia Therapies and Research Center. The centre will integrate the expertise of the world-class research and clinical programs at Cincinnati Children’s and increase patient access to cutting-edge clinical trials.
Why Purchase the Report?
- To visualize the global pediatric oncology drugs market segmentation based on drug type, indication, route of administration, end user and region as well as understand key commercial assets and players.
- identify commercial opportunities by analyzing trends and co-development.
- excel data sheet with numerous data points of the pediatric oncology drugs market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global pediatric oncology drugs market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
